Virocell Biologics
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
Virocell Biologics firmographics
Firmographics- Name
- Virocell Biologics
- Legal name
- ViroCell Holdings Limited
- Website
- https://virocell.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Virocell Biologics industry classification
Industry- Product category
- Viral Vector CDMO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Virocell Biologics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Virocell Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- CDMO Manufacturing Services: Contract development and manufacturing organization providing lentiviral and retroviral vector manufacturing services for clinical trials. Revenue generated through project-based contracts with biotech and pharma clients requiring GMP-grade vector production. Services include research-grade and GMP manufacturing with quality release (QP-released vectors) in timelines as short as six months.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Virocell Biologics product offering
Product offeringCore offering
Virocell Biologics is an innovation-driven contract development and manufacturing organization (CDMO) focused exclusively on lentiviral and retroviral vectors. The company provides an integrated suite of services spanning vector design, optimization, process development, and GMP manufacturing to support cell and gene therapy developers transitioning candidates from the lab to clinical trials. Its streamlined platform enables delivery of GMP-grade lentiviral vectors in approximately six months for accelerated programs.
Product overview
ViroCell Biologics is an innovation-driven lentiviral and retroviral vector CDMO (Contract Development and Manufacturing Organization) offering an integrated suite of services spanning from design to GMP manufacturing. The core offerings include Innovation Research for developing new manufacturing technologies and safer vectors, Viral Vector Design & Optimization leveraging their proprietary vector backbone portfolio, Viral Vector Process Development focused on yield improvements, and GMP Lentiviral & Retroviral Vector Manufacturing with a streamlined six-month delivery platform. These services are unified by a Modular Lentiviral Platform backbone that can be customized with disease-specific elements. Key differentiating technologies include Ligand-Directed Pseudotyping for tissue-specific targeting, Click Chemistry Vector Modification for post-production surface functionalization, a Dual-Phase Production Platform combining early-stage rapid generation with GMP-ready stable producer lines, Regulated VSVg Expression Systems for stable high-titer production, Suspension Cell Line Development for scalable bioreactor manufacturing, Non-Integrating Lentiviral Vectors for safety-critical applications, and Ligand Display Technology for precision targeting.
Differentiator
Problem solved
Functional benefit
Products and services
- Innovation Research Research service in which Virocell's innovation team develops new manufacturing technologies and more effective and safer lentiviral and retroviral vectors for cell and gene therapy developers.
- Viral Vector Design & Optimization CDMO service leveraging Virocell's vector backbone portfolio to design and manufacture multiple lentiviral or retroviral vector candidates so clients can refine performance evaluation before GMP manufacturing.
- Viral Vector Process Development CDMO service focused on process optimization to deliver significant improvements in critical lentiviral and retroviral vector yields for gene therapy manufacturing programs.
- GMP Lentiviral & Retroviral Vector Manufacturing CDMO GMP manufacturing service providing streamlined platform-based production of clinical-grade lentiviral and retroviral vectors with delivery in approximately six months for accelerated programs.
Quantifiable outcome
- Fourfold increase in vector titer through small molecule additive addition in transient transfection production
- +3 more outcomes
Companies that use Virocell Biologics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Virocell Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature13 records
Virocell Biologics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Great Ormond Street Hospital (GOSH)coreViroCell is proud to be working in partnership with Great Ormond Street Hospital (GOSH), a leading pediatric healthcare institution. The partnership supports GOSH's viral vector manufacturing operations, including GOSH's receipt of new MHRA authorisation to manufacture viral vectors for clinical applications. GOSH represents a key reference customer and collaborative partner in advancing pediatric gene therapies.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Virocell Biologics competitors and assessment
Company assessmentDirect peers
- Yposkesi: European lentiviral and AAV viral vector CDMO serving cell and gene therapy developers. Direct competitor to ViroCell in lentiviral vector manufacturing for clinical trials, with comparable B2B CDMO model.
- Cobra Biologics (Charles River Laboratories): Long-established viral vector and plasmid DNA CDMO with deep lentiviral manufacturing heritage, now part of Charles River. Directly comparable as a lentiviral CDMO serving cell and gene therapy clinical programs.
- Andelyn Biosciences: Viral vector CDMO specializing in AAV and lentiviral manufacturing for gene therapy developers. Competes with ViroCell for lentiviral vector programs targeting cell and gene therapy trials.
- Forge Biologics: Viral vector and gene therapy CDMO offering lentiviral and AAV manufacturing at clinical and commercial scale. Comparable as a one-stop lentiviral CDMO for cell and gene therapy developers.
- Vibalogics: Specialized CDMO focused on viral vectors (lentiviral, retroviral, AAV) and oncolytic viruses for clinical trials. Direct competitor in the lentiviral/retroviral CDMO niche.
- Genezen: Viral vector CDMO offering lentiviral and AAV manufacturing and process development services to gene therapy developers. Comparable lentiviral-focused CDMO targeting clinical-stage programs.
Broad incumbents
- BioReliance (MilliporeSigma): Large-scale biopharmaceutical CDMO services arm of MilliporeSigma offering viral vector manufacturing and biosafety testing. A broader incumbent with overlapping lentiviral CDMO capabilities.
- AGC Biologics: Global CDMO offering cell and gene therapy services including viral vector manufacturing. A broad incumbent with lentiviral capabilities competing for larger commercial-stage programs.
- Thermo Fisher Scientific Viral Vector Services: Global life sciences services arm offering viral vector CDMO capabilities including lentiviral manufacturing. Broad incumbent with significant scale advantages over ViroCell.
- Ology Bioservices (National Resilience): CDMO providing viral vector and biologics manufacturing services including lentiviral vectors. Broad incumbent competing across gene therapy manufacturing programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Virocell Biologics social profiles
Digital presenceVirocell Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Virocell Biologics leadership team
Management profileNumber of profiles
Profiles5 records
Virocell Biologics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Virocell Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Virocell Biologics
What does Virocell Biologics do?
Virocell Biologics is an innovation-driven contract development and manufacturing organization (CDMO) focused exclusively on lentiviral and retroviral vectors. The company provides an integrated suite of services spanning vector design, optimization, process development, and GMP manufacturing to support cell and gene therapy developers transitioning candidates from the lab to clinical trials. Its streamlined platform enables delivery of GMP-grade lentiviral vectors in approximately six months for accelerated programs.
Is Virocell Biologics a public or private company?
Virocell Biologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Virocell Biologics founded?
Virocell Biologics was founded in 2021. It employs 1 to 10 people.
Where is Virocell Biologics based?
Virocell Biologics is headquartered in London, United Kingdom, in the Europe region.
How does Virocell Biologics make money?
One revenue line is on record: CDMO Manufacturing Services.
Who are Virocell Biologics's main competitors?
Direct peers on record are Yposkesi, Cobra Biologics (Charles River Laboratories), Andelyn Biosciences, Forge Biologics, Vibalogics and Genezen. Broad incumbents are BioReliance (MilliporeSigma), AGC Biologics, Thermo Fisher Scientific Viral Vector Services and Ology Bioservices (National Resilience).
Does Virocell Biologics have an API?
No public API is recorded for Virocell Biologics.
What industry is Virocell Biologics in?
Virocell Biologics's product category is Viral Vector CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 541714 and its SIC code is 2836.